Corvus Pharmaceuticals (CRVS) Free Cash Flow Growth (1y) (2016 - 2026)
Powered by 
Analysis
Corvus Pharmaceuticals (CRVS) Free Cash Flow Growth (1y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 9.25% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -38.10% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 38.94% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 96.00% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 152.82% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 31.57% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 58.53% |
| 10 | Corvus Pharmaceuticals | 1.33 Bn | 1.12 Bn | - | -180.65% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -180.65% |
| Mar 31, 2026 | -27.92% |
| Dec 31, 2025 | 2.72% |
| Sep 30, 2025 | -57.31% |
| Jun 30, 2025 | -9.63% |
| Mar 31, 2025 | -67.88% |
| Dec 31, 2024 | -130.21% |
| Sep 30, 2024 | -10.91% |
| Jun 30, 2024 | 0.56% |
| Mar 31, 2024 | 40.17% |
| Dec 31, 2023 | 35.53% |
| Sep 30, 2023 | 24.46% |
| Jun 30, 2023 | 14.70% |
| Mar 31, 2023 | -26.79% |
| Dec 31, 2022 | 7.46% |
| Sep 30, 2022 | 14.23% |
| Jun 30, 2022 | 48.48% |
| Mar 31, 2022 | 32.03% |
| Dec 31, 2021 | 15.18% |
| Sep 30, 2021 | -7.26% |